NewAmsterdam targets obicetrapib launch after SPAC deal

26 July 2022
newamsterdam_pharma_large

Dutch firm NewAmsterdam Pharma Holding and Frazier Lifesciences Acquisition Corporation, a special purpose acquisition company (SPAC) sponsored by an affiliate of Frazier Healthcare Partners, have agreed to merge.

Upon closing of the transaction, a newly-formed holding company, NewAmsterdam Pharma Company, will be listed on Nasdaq under the ticker symbol NAMS.

The company will be led by Michael Davidson, the current chief executive of the Naarden-based firm, which is focused on the research and development of transformative oral therapies for major cardiometabolic diseases.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology